Overview

A Study to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone in Short Stature Children Due to Chronic Kidney Disease Before Transplantation

Status:
Unknown status

Trial end date:
2021-09-01

Target enrollment:

Participant gender:

Summary

This study aims to evaluate the efficacy and safety of recombinant human growth hormone injection in short stature children due to chronic kidney disease before transplantation.

Phase:

Phase 3

Details

Lead Sponsor:

GeneScience Pharmaceuticals Co., Ltd.

Collaborators:

Beijing Children's Hospital
Children's hospital capital institute of pediatrics
Children's Hospital of Chongqing Medical University
Children's Hospital of Fudan University
Children's Hospital of Shanghai
Children's Hospital of The Capital Institute of Pediatrics
Fuzhou General Hospital
Peking University First Hospital
Shanghai Children's Hospital
Shengjing Hospital
The Children's Hospital of Zhejiang University School of Medicine
The First Affiliated Hospital of Zhengzhou University
Tongji medical college huazhong university of science & technology
Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

Treatments:

Hormones